Brooks Laboratories Ltd Stock Price Today (NSE: BROOKS)
Fundamental Score
Brooks Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Brooks Laboratories Ltd share price today is ₹67.05, down 2.19% on NSE/BSE as of 19 June 2026. Brooks Laboratories Ltd (BROOKS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹296.77 (Cr). The 52-week high for BROOKS share price is ₹164.02 and the 52-week low is ₹36.30. At a P/E ratio of 21.24x, BROOKS is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -12.21% and a debt-to-equity ratio of 0.07.
Brooks Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Brooks Laboratories Ltd share price chart: -3.58% return over the past month. 52-week high ₹164.02, 52-week low ₹36.30.
Brooks Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹68.55 | ₹71.90 | ₹65.13 | ₹67.05 | 1.23L (Cr) | |
| ₹68.55 | ₹68.55 | ₹67.50 | ₹68.55 | 1.68L (Cr) | |
| ₹65.29 | ₹65.29 | ₹65.29 | ₹65.29 | 33.39K (Cr) | |
| ₹62.00 | ₹62.19 | ₹58.00 | ₹62.19 | 1.18L (Cr) | |
| ₹59.23 | ₹59.23 | ₹59.23 | ₹59.23 | 55.05K (Cr) | |
| ₹54.89 | ₹56.41 | ₹54.54 | ₹56.41 | 42.94K (Cr) | |
| ₹51.25 | ₹53.73 | ₹51.25 | ₹53.73 | 53.84K (Cr) | |
| ₹50.64 | ₹51.50 | ₹49.00 | ₹51.18 | 44.59K (Cr) | |
| ₹49.39 | ₹50.04 | ₹47.11 | ₹49.51 | 59.39K (Cr) | |
| ₹46.95 | ₹48.42 | ₹46.50 | ₹48.42 | 50.83K (Cr) |
Brooks Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹68.55 | ₹71.90 | ₹65.13 | ₹67.05 | -2.19% | |
| ₹56.15 | ₹65.29 | ₹44.56 | ₹65.29 | +16.28% | |
| ₹38.98 | ₹79.70 | ₹38.98 | ₹55.98 | +43.61% | |
| ₹63.50 | ₹65.88 | ₹36.30 | ₹37.11 | -41.56% | |
| ₹61.98 | ₹82.44 | ₹58.35 | ₹67.11 | +8.28% | |
| ₹80.50 | ₹80.58 | ₹61.32 | ₹61.55 | -23.54% | |
| ₹103.99 | ₹105.65 | ₹68.11 | ₹80.14 | -22.93% | |
| ₹113.25 | ₹113.69 | ₹95.25 | ₹102.20 | -9.76% | |
| ₹134.25 | ₹138.34 | ₹104.51 | ₹110.93 | -17.37% | |
| ₹135.00 | ₹163.90 | ₹132.99 | ₹134.25 | -0.56% | |
| ₹157.04 | ₹164.02 | ₹133.25 | ₹134.70 | -14.23% | |
| ₹145.97 | ₹162.13 | ₹134.62 | ₹153.97 | +5.48% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Micro-cap CDMO banking on a JV turnaround, but liquidity and execution risks loom large.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Brooks Laboratories faced scrutiny from the Exchange regarding significant price movement, with a clarification sought on April 1, 2026. The company responded on April 2, 2026, stating that all material information had been disclosed and attributed price fluctuations to market forces. Earlier, on April 6, 2026, the stock hit its upper circuit of 20%, closing at , with buyers lined up and no sellers, reflecting strong buying pressure.
CORE STORY (THE REAL GAME)
Brooks Laboratories is a micro-cap CDMO player attempting to scale up in a consolidating pharma landscape. The market is trying to figure out if it can transition from a contract manufacturer to a player with proprietary ANDAs and global market access.
- Upper circuit momentum
- BSL scheme of arrangement updates
- Improved Q3 earnings
- Successful penetration of regulated markets with carbapenems
- Significant order wins
- Positive developments regarding the BSL joint venture
- Micro-cap liquidity risk
- Negative ROE and ROCE
- Reliance on joint ventures
FII increased holdings to 0.01%, a negligible amount. DII holdings remain at 10.38%.
Indian pharma exports are growing, projected to reach $130 billion by 2030, but global pricing pressures persist.
Profit is not converting to cash. Free Cash Flow 5Y is ₹-86.78 Cr.
BSL's success in expanding manufacturing and penetrating global markets is crucial. Watch for execution and order wins over the next 6 months.
Primary Thesis Risk
BSL joint venture fails to deliver, leaving Brooks stranded with stretched liquidity.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Brooks Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Brooks Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BROOKS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.24 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (301.52%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (13.63x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (52.62%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-12.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-9.93%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-17.61%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Negative Free Cash Flow (₹-86.78 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Brooks Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Brooks Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Brooks Laboratories LtdBrooks Laborato...Selected✓ BROOKS • 533543 | 32/100 | ₹67.05₹67 | ₹296.77₹296.77 | 21.24Average 21.2 Average | -12.21%Poor -12.21% Poor | -9.93%Poor -9.93% Poor | 0.07Excellent 0.1 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Brooks Laboratories Ltd Quarterly Performance
Latest quarterly metrics for BROOKS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.79%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
301.52%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Brooks Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BROOKS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Brooks Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Brooks Laboratories Ltd (BROOKS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Brooks Laboratories Ltd
About BROOKS (Brooks Laboratories Ltd)
Brooks Laboratories Ltd is a dynamic pharmaceutical manufacturer carving a niche for itself in the complex world of drug development and production. They operate as a comprehensive... service provider, collaborating with pharmaceutical companies across India and global markets. Brooks Labs offers a unique blend of innovative solutions and rigorous quality control, functioning as a trusted partner throughout the drug lifecycle. From the initial stages of formulation and analytical development to large-scale commercial manufacturing, the company demonstrates a commitment to precision and efficiency. They aim to empower their partners to bring innovative medications to the market, ensuring accessibility and improved patient outcomes through reliable and cost-effective production processes. The core of Brooks Laboratories' capabilities lies in its diversified manufacturing platform, designed to handle a wide spectrum of pharmaceutical dosage forms. This encompasses advanced sterile injectables, including both liquid and lyophilized formats, crucial for delivering critical medications directly into the bloodstream. Beyond injectables, they also specialize in the production of diverse solid oral dosage forms. These include conventional tablets and specialized dry powder syrups, catered to patient populations of all ages. Furthermore, Brooks Labs maintains dedicated facilities for manufacturing specialized products like ophthalmic and nasal solutions, demonstrating their versatility and commitment to meeting varied therapeutic needs. With this wide-ranging production capacity, Brooks Laboratories positions itself as a versatile manufacturing solution for pharmaceutical innovators. Focusing on critical therapeutic areas, Brooks Laboratories offers robust manufacturing capabilities in high-demand segments like anti-infectives, pain management, and oncology. Their expertise in handling potent and cytotoxic substances allows them to produce complex formulations with precision and safety. These products are often essential treatments for serious illnesses and chronic conditions. Through rigorous adherence to international quality standards and dedicated facilities, Brooks Laboratories ensures the integrity and efficacy of every product they manufacture. This commitment to excellence allows the company to contribute significantly to the global healthcare ecosystem, providing access to life-saving medications and improved quality of life for patients worldwide.
Company Details
Key Leadership
Latest News
BROOKS Share Price: Frequently Asked Questions
What is the current share price of Brooks Laboratories Ltd?
Brooks Laboratories Ltd (BROOKS) trades at ₹67.05 on NSE and BSE. Market cap ₹296.77 (Cr). Educational data only.
What is the P/E ratio of Brooks Laboratories Ltd?
Brooks Laboratories Ltd has a P/E of 21.24x vs industry average 31.77x.
What is the Bull Run score for Brooks Laboratories Ltd?
Brooks Laboratories Ltd has a Bull Run score of 32/100 based on 25+ financial parameters.
Does Brooks Laboratories Ltd pay dividends?
Brooks Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Brooks Laboratories Ltd?
Brooks Laboratories Ltd has ROE of -12.21%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Brooks Laboratories Ltd?
Brooks Laboratories Ltd has debt-to-equity of 0.07.
Is Brooks Laboratories Ltd a good investment?
Bull Run gives Brooks Laboratories Ltd a score of 32/100. This is not investment advice — consult a SEBI-registered advisor.